CG Oncology, Inc. (CGON)

CG Oncology Stock Forecast

Stock Price Forecast

The 11 analysts that cover CG Oncology stock have a consensus rating of "Strong Buy" and an average price target of $70.82, which forecasts a 24.27% increase in the stock price over the next year. The lowest target is $47 and the highest is $90.

Price Target: $70.82 (+24.27%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$47	$70.82	$75	$90
Change	-17.53%	+24.27%	+31.60%	+57.92%

Analyst Ratings

The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26
Strong Buy	6	7	6	6	5	5
Buy	6	6	5	6	6	6
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	13	11	12	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gregory Renza Truist Securities	Truist Securities	Strong Buy Maintains $66 → $75	Strong Buy	Maintains	$66 → $75	+31.60%	Feb 10, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $61 → $73	Buy	Maintains	$61 → $73	+28.09%	Jan 21, 2026
Kelsey Goodwin Piper Sandler	Piper Sandler	Buy Maintains $55 → $70	Buy	Maintains	$55 → $70	+22.83%	Jan 16, 2026
Gregory Renza Truist Securities	Truist Securities	Strong Buy Maintains $62 → $66	Strong Buy	Maintains	$62 → $66	+15.81%	Jan 12, 2026
Robert Driscoll Wedbush	Wedbush	Buy Initiates $70	Buy	Initiates	$70	+22.83%	Dec 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.85M

Increased by 62.77%

from 1.14M

Revenue Next Year

33.69M

Increased by 1,716.88%

from 1.85M

EPS This Year

-2.22

from -1.41

EPS Next Year

-2.66

from -2.22

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	10.36M	191.00K	204.00K	1.14M	1.85M	33.69M	120.91M
Revenue Growth	-	-98.16%	6.81%	458.33%	62.77%	1,716.88%	258.94%
EPS	-5.04	-11.71	-15.65	-1.41	-2.22	-2.66	-2.36
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	17	17	15

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	2.4M	116.5M
Avg	1.9M	33.7M
Low	1.7M	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	112.0%	6,183.7%
Avg	62.8%	1,716.9%
Low	46.3%	-

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-2.22	-1.43
Avg	-2.22	-2.66
Low	-2.21	-3.26

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.